All Title Author
Keywords Abstract

Effectiveness of glucose-insulin–potassium treatment in nondiabetic patients with acute myocardial infarction

Keywords: Myocardial infarction , glucose , insulin , potassium

Full-Text   Cite this paper   Add to My Lib


Objective: Glucose- insulin-potassium (GIK) treatment given additional to standard therapy effectiveness was investigated in nondiabetic patients with acute myocardial infarction. Material and Method: 29 nondiabetic patients with acute myocardial infarction participated between January and June 2005 in Taksim Training and Research Hospital Coronary Care Unit. Besides standard therapy 14 patients received GIK solution while 15 patients did not. The cardiac enzyme increasing velocity differences were investigated. All patients investigated were nondiabetics. Myocardial infarction was diagnosed by chest pain, electrocardiography and cardiac enzyme assessments. Blood samples for creatin phosphokinase, CPK-MB, myoglobine, Troponin-I and C-reactive protein (CRP) were enrolled at index and further after 6th, 12th and 24th hours. Results: No difference was detected regarding age, body weight, height, application time and lipid profiles between two groups. Although index of 6th and 12th hour controls showed no difference, 24th hour values showed statistically significant difference with a p=0.0013. CRP level in GIK group was 22.56±12.95 mg/dL and 78.92±69.94 mg/dL in non-GIK group. In our assessment using DUNN’s multiple comparison test, although in the group receiving GIK, there was a statistically significant difference accordingly Troponin-I initial and 6th, 12th hours; there was no difference in the given GIK and non GIK group. In comparison of the CRP levels at index and at 24th hour p values were found less than 0,05 (p<0,05) in both groups. Conclusion: In our study, we realized that in the group given GIK; some of the myocardial injury markers were decreasing and finally decided that GIK solution could be beneficial in diabetic and nondiabetic patients.


comments powered by Disqus